Xin Lang Cai Jing·2025-09-08 07:45Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The company is headquartered in Shanghai, China, and operates in the biopharmaceutical sector, specifically in the development of innovative drugs [7]. Product Development - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - Junshi's subsidiary, JunTuo Biotech, is collaborating with research institutions to develop vaccines, including those for monkeypox and Zika, which are currently in preclinical development [3]. - A partnership has been established with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase in losses [8]. - As of June 30, 2025, the number of shareholders increased to 31,200, with an average of 24,543 shares held per shareholder, a decrease of 5.56% [8]. Market Activity - On September 8, 2023, Junshi's stock price decreased by 0.98%, with a trading volume of 867 million yuan and a market capitalization of 48.799 billion yuan [1]. - The stock has shown no clear trend in major fund inflows, with a net outflow of 7.31 million yuan on the same day [4][5].